News
CLYM
13.00
+2.71%
0.34
Analysts Offer Insights on Healthcare Companies: MiMedx Group (MDXG), Climb Bio (CLYM) and Ionis Pharmaceuticals (IONS)
TipRanks · 1d ago
Climb Bio Price Target Maintained With a $20.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Climb Bio, Maintains $20 Price Target
Benzinga · 2d ago
Climb Bio Buy Rating Reiterated as Advancing Pipeline Supports Maintained $20 Price Target
TipRanks · 2d ago
Weekly Report: what happened at CLYM last week (0615-0619)?
Weekly Report · 4d ago
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Climb Bio (CLYM) and Intuitive Surgical (ISRG)
TipRanks · 06/15 11:31
Weekly Report: what happened at CLYM last week (0608-0612)?
Weekly Report · 06/15 09:50
Climb Bio Establishes New At-the-Market Equity Program
TipRanks · 06/12 22:46
CLIMB BIO - MAY OFFER AND SELL UP TO $100 MLN OF COMMON STOCK - SEC FILING
Reuters · 06/12 20:37
Climb Bio enters Jefferies ATM equity distribution agreement for up to $100 million stock sale
PUBT · 06/12 20:37
Climb Bio Launches $100M At-The-Market Common Stock Offering Via Jefferies
Benzinga · 06/12 20:25
Why Is Climb Bio Stock Gaining Friday?
Benzinga · 06/12 14:19
Climb Bio Price Target Maintained With a $17.00/Share by Wedbush
Dow Jones · 06/12 14:09
Wedbush Reiterates Outperform on Climb Bio, Maintains $17 Price Target
Benzinga · 06/12 13:59
Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), DENTSPLY SIRONA (XRAY) and Climb Bio (CLYM)
TipRanks · 06/12 12:50
Analysts Offer Insights on Healthcare Companies: Schrodinger (SDGR) and Climb Bio (CLYM)
TipRanks · 06/11 16:00
Climb Bio Price Target Raised to $20.00/Share From $19.00 by BTIG
Dow Jones · 06/11 15:52
Climb Bio Is Maintained at Buy by BTIG
Dow Jones · 06/11 15:52
BTIG Maintains Buy on Climb Bio, Raises Price Target to $20
Benzinga · 06/11 15:41
Climb Bio announces initial data from budoprutug study at EHA
TipRanks · 06/11 12:05
More
Webull provides a variety of real-time CLYM stock news. You can receive the latest news about Climb Bio through multiple platforms. This information may help you make smarter investment decisions.
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.